Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination | Zendy

Sidonie Lambert-Niclot | Zendy; Clotilde Allavena | Zendy; Maxime Grudé | Zendy; Philippe Flandre | Zendy; Sophie Sayon | Zendy; Emmanuel André | Zendy; Marc Wirden | Zendy; Audrey Rodallec | Zendy; T Jovelin | Zendy; Christine Katlama | Zendy; Vincent Cálvez | Zendy; François Raffi | Zendy; AnneGeneviève Marcelin | Zendy

Open Access

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination

Author(s) -

Sidonie Lambert-Niclot,

Clotilde Allavena,

Maxime Grudé,

Philippe Flandre,

Sophie Sayon,

Emmanuel André,

Marc Wirden,

Audrey Rodallec,

T Jovelin,

Christine Katlama,

Vincent Cálvez,

François Raffi,

AnneGeneviève Marcelin

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw146

Subject(s) - rilpivirine , emtricitabine , resistance mutation , virology , genotype , drug resistance , genotyping , medicine , tenofovir , viral load , reverse transcriptase , rna , human immunodeficiency virus (hiv) , biology , antiretroviral therapy , genetics , gene

In the context of a rilpivirine/emtricitabine/tenofovir disoproxil fumarate switch in HIV-1-infected patients with at least 1 year of virological success, we determined whether proviral DNA is an alternative to plasma HIV RNA for resistance genotyping.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research